Abbott Laboratories (NYSE:ABT) closed its last session at $41.89 with the change of +1.28%. The market capitalization of the company is $61.54B with an average Volume of 10.87 million shares. The stock currently has its 52-Week High range of $51.74 and 52-week low range of $36.00. The Price to Book (P/B) ratio stands at 2.93. The stock traded total quantity of 11.07 million shares.
For the current Fiscal Quarter, 19 analysts have given an average earnings per share forecast of $0.53. The Low Earnings per share estimate of the current Quarter is $0.52 and High Estimate is set at $0.58 according to these Analysts opinions. The Previous Year EPS of this Quarter is $0.52.
According to 18 analysts, an average sales Estimate of the current Fiscal quarter is $5.24B. The lower sales estimate is $5.12B and higher sales estimate is $5.31B according to these Analysts thoughts.
The Company currently has Highest Price Target of $49 and Lowest Price Target of $42. It has Median Price Targets of $47. Mean price target is set at $46.6 after consensus analysis of 15 brokers.
When having look at Recommendation Trends of the analysts polled at Thomson First call, for the Current month 6 analysts have assigned this stock as Strong Buy where 8 assigned Buy, 6 analysts believe it’s a Hold, 0 said Underperform and 0 assigned Sell rating.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) ended its last trade at $4.64 with the move of -0.22%. The company has market value of $458.05M with the total traded volume of 1.49 million. The stock currently has its 52-Week top value of $28.08 and 52-week down value of $2.96. The price to book (P/B) ratio of the company is 1.77. Its previous closing price was recorded at $4.65.
For the current Fiscal Quarter, 10 analysts have given an Average earnings estimate of $-0.33 per share. According to the Analysts, the Low Estimate Earnings of the current Quarter is $-0.36 while High Estimate is $-0.29. The Previous Year EPS of this Quarter is $-0.33.
According to 9 analysts, an Average Revenue Estimate of the current Fiscal quarter is $850.00K. According to them, the Low Revenue estimate is $NaN and High Revenue estimate is $1.40M.